NCT00625014

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Leiden University Medical Center · Academic / Other
• Sex: Male
• Age: 20 Years – 40 Years
• Healthy volunteers: Accepted

Summary

We hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. We therefore treated healthy non-obese men with haloperidol for 8 days, and studied the impact of these intervention on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.

Conditions

• Insulin Resistance
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Haloperidol	Haloperidol 3 mg/day for 8 days

Timeline

• Start date: 2005-03-01
• Primary completion: 2005-07-01
• Completion: 2005-07-01
• First posted: 2008-02-28
• Last updated: 2019-08-26

Locations

1 site across 1 country: Netherlands